Financial StabilityThe cash position of the company is strong, which supports its operational stability.
Product DevelopmentAdicet is developing ADI-212, a PSMA targeting candidate for prostate cancer, which has shown anti-tumor efficacy in studies.
Regulatory ApprovalADI-001 has been granted FDA Fast Track Designation for the treatment of adult patients with refractory systemic lupus erythematosus, systemic sclerosis, and relapsed or refractory class III or class IV lupus nephritis.